Nexo Therapeutics, Inc. — Form D/A
Nexo Therapeutics, Inc. of LITTLETON, CO, a company, filed a Form D amendment with the SEC on 2025-09-17. The offering totals $60.0M, of which $52.5M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2025-09-17
- Form: D/A
- Accession: 0001955319-25-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $60.0M
- Amount sold: $52.5M
- Remaining: $7.5M
- Investors: 7
- Date of first sale: 2022-11-15
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-465438
Issuer
- Name: Nexo Therapeutics, Inc.
- CIK: 0001955319
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2022
- Address: 11757 W. KEN CARYL AVENUE, LITTLETON, CO, 80127-3719
- Phone: 303-868-6790
Officers, directors & promoters (8)
| Name | Role | Location |
|---|
| Ali Behbahani | Director | Littleton, CO |
| Andrew Phillips | Director | New York, NY |
| Carlo Rizzuto | Director | Littleton, CO |
| Andrew Phillips | Executive Officer | New York, NY |
| Michael Kim | Executive Officer | George Town, Grand Cayman, E9 |
| Ali Behbahani | Related Person | Littleton, CO |
| Andrew Phillips | Related Person | New York, NY |
| Carlo Rizzuto | Related Person | Littleton, CO |
Other filings by this issuer (3)
More